In patients with advanced NSCLC and without any mutation in the EGFR gene, docetaxel provides significantly improved progression-free survival compared to erlotinib, according to a phase III randomized trial.
ASCO: MEK Inhibitors—Alone or Paired With a BRAF Inhibitor—Increase Options, Benefits for Patients With BRAF-Mutated Advanced Melanoma
At the ASCO annual meeting, researchers presented persuasive evidence that a new class of targeted agents—MEK inhibitors—may warrant inclusion in the growing armamentarium for patients with advanced BRAF-mutated melanoma.
Women with metastatic HER2-positive breast cancer treated with a taxane-based chemotherapy in combination with trastuzumab as a first-line of treatment have a longer progression-free survival compared to chemotherapy in combination with lapatinib (Tykerb)
ASCO: Phase II/III Data Establish Dabrafenib as Second BRAF Inhibitor With Proven Efficacy in Metastatic Melanoma
Data from the phase III BREAK-3 and the phase II BREAK-MB trials of dabrafenib establish the drug as the second BRAF inhibitor for BRAF V600E-mutated melanoma.
Researchers reported results of an international phase III trial showing that intermittent hormonal therapy is less effective than continuous therapy in prostate cancer with minimal disease.
Patients with EGFR mutation-positive lung cancer had improved progression-free survival and better quality of life with new drug afatinib than with standard chemotherapy, according to results from a large phase III trial.
The class of agents that target the Programmed Death 1 (PD-1) pathway was described at ASCO as “likely the most exciting new agents recently developed in melanoma.”
Updated data from an ongoing phase II trial of oral sapacitabine showed that the drug had activity in older patients with myelodysplastic syndromes refractory to front-line hypomethylating agents indicates.
The use of fluorodeoxyglucose positron emission tomography (FDG-PET), for diagnosing lung cancer may have to be rethought. According to an analysis of data from a national prospective trial, FDG-PET has substantially lower sensitivity and specificity than in previously published studies.
ASCO: Adding Abiraterone to Leuprolide Before Prostatectomy Can Eliminate Tumor in Some Men With High-Risk Prostate Cancer
Results from a randomized phase II study show that 6 months of treatment with abiraterone (Zytiga), in addition to the hormone therapy leuprolide before prostatectomy, resulted in complete response and near-complete response in one-third of men with high-risk prostate cancer.